Skip to content
No PriorsNo Priors

“Curing All Disease by next century is too conservative" - Mark Zuckerberg

Biohub started with an ambitious goal of curing, preventing, and managing all disease by the end of the century. A decade later, thanks to the convergence of frontier AI and biological data, that goal may have been too conservative. In this episode, Elad Gil and Sarah Guo sit down with Biohub co-founders Mark Zuckerberg and Priscilla Chan, alongside Biohub Head of Science Alex Rives. Together, they discuss Biohub’s $500 million virtual biology initiative, which integrates frontier AI with wet-lab work to build predictive world models of cells, proteins, and systems. They also talk about their newly announced open-source engine for digital protein and antibody design, ESMFold2; why Biohub is a nonprofit rather than a venture-backed startup; and how hierarchical simulations will soon allow doctors to treat patients at an individual, mechanistic level. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @Biohub | @finkd | @alexrives | @ChanZuckerberg Chapters: 00:00 – Cold Open 01:02 - Mark Zuckerberg, Priscilla Chan, and Alex Rives Introduction 01:26 – Why Biohub and Their Mission 08:27 – Integrating Frontier AI and Frontier Biology 09:45 – Micro to Macro Biological Modeling 14:22 – Mechanistic Interpretiability 16:58 – Why Biohub is a Non-Profit 21:41 – Understanding How Biology Works 24:23 – Timeline for Curing All Diseases 26:25 – Translating Research to Patient Impact 28:04 – Launch of ESMFold2 32:13 – Tackling Off-Target Effects and Edge Cases 38:39 – Putting the Tech in Individual Hands 41:06 – Talent at Biohub 44:25 – What’s Next After ESMFold2 46:10 – Connecting ESMFold2 to Agentic Systems 46:51 – The Virtual Cell 49:33 – Defining Success for Biohub 51:52 – Biohub Strategy Update 56:20 – Conclusion

Mark ZuckerbergguestAlex RivesguestSarah GuohostElad Gilhost
Jun 10, 202656mWatch on YouTube ↗

Episode Details

EPISODE INFO

Released
June 10, 2026
Duration
56m
Channel
No Priors
Watch on YouTube
▶ Open ↗

EPISODE DESCRIPTION

Biohub started with an ambitious goal of curing, preventing, and managing all disease by the end of the century. A decade later, thanks to the convergence of frontier AI and biological data, that goal may have been too conservative. In this episode, Elad Gil and Sarah Guo sit down with Biohub co-founders Mark Zuckerberg and Priscilla Chan, alongside Biohub Head of Science Alex Rives. Together, they discuss Biohub’s $500 million virtual biology initiative, which integrates frontier AI with wet-lab work to build predictive world models of cells, proteins, and systems. They also talk about their newly announced open-source engine for digital protein and antibody design, ESMFold2; why Biohub is a nonprofit rather than a venture-backed startup; and how hierarchical simulations will soon allow doctors to treat patients at an individual, mechanistic level. Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @Biohub | @finkd | @alexrives | @ChanZuckerberg Chapters: 00:00 – Cold Open 01:02 - Mark Zuckerberg, Priscilla Chan, and Alex Rives Introduction 01:26 – Why Biohub and Their Mission 08:27 – Integrating Frontier AI and Frontier Biology 09:45 – Micro to Macro Biological Modeling 14:22 – Mechanistic Interpretiability 16:58 – Why Biohub is a Non-Profit 21:41 – Understanding How Biology Works 24:23 – Timeline for Curing All Diseases 26:25 – Translating Research to Patient Impact 28:04 – Launch of ESMFold2 32:13 – Tackling Off-Target Effects and Edge Cases 38:39 – Putting the Tech in Individual Hands 41:06 – Talent at Biohub 44:25 – What’s Next After ESMFold2 46:10 – Connecting ESMFold2 to Agentic Systems 46:51 – The Virtual Cell 49:33 – Defining Success for Biohub 51:52 – Biohub Strategy Update 56:20 – Conclusion

SPEAKERS

  • Mark Zuckerberg

    guest

    CEO of Meta and co-founder of the Chan Zuckerberg Initiative (CZI), involved in setting CZI/Biohub strategy and priorities.

  • Alex Rives

    guest

    Computational biologist known for protein foundation models (ESM/ESMFold) and leading AI-for-biology efforts at CZ Biohub.

  • Sarah Guo

    host

    Co-host of No Priors and venture capitalist (founder/managing partner at Conviction) focused on AI and startups.

  • Elad Gil

    host

    Co-host of No Priors; entrepreneur and investor known for work with high-growth technology companies and AI talent/hiring.

EPISODE SUMMARY

In this episode of No Priors, featuring Mark Zuckerberg and Alex Rives, “Curing All Disease by next century is too conservative" - Mark Zuckerberg explores biohub’s open-source AI and biology platform to accelerate medicine Biohub’s core thesis is that the fastest path to medical breakthroughs is building shared, open tools and datasets that the entire scientific community can use, rather than trying to “cure diseases” as a single centralized organization.

RELATED EPISODES

Building an Autonomous Delivery Experience with DoorDash Co-Founders Andy Fang and Stanley Tang

Building an Autonomous Delivery Experience with DoorDash Co-Founders Andy Fang and Stanley Tang

Travel Through the Lens of AI with with Booking.com CEO Glenn Fogel

Travel Through the Lens of AI with with Booking.com CEO Glenn Fogel

How Nuclear Will Unlock Energy Abundance with Valar Atomics Founder Isaiah Taylor

How Nuclear Will Unlock Energy Abundance with Valar Atomics Founder Isaiah Taylor

Pax Silica: Inside the Trump Administration’s Tech Strategy with Jacob Helberg

Pax Silica: Inside the Trump Administration’s Tech Strategy with Jacob Helberg

No Priors Ep 66 | With Y Combinator President and CEO Garry Tan

No Priors Ep 66 | With Y Combinator President and CEO Garry Tan

No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute

No Priors Ep. 103 | With Vevo Therapeutics and the Arc Institute

Get more out of YouTube videos.

High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.